Please assess the completion status of the following clinical trial:

Trial Title: Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven glioblastoma~* Stable disease following ≥ 4 cycles of adjuvant temozolomide~* No progression or recurrence of disease~PATIENT CHARACTERISTICS:~* HLA-A\*02 positive~* ≥ 18 years old~* Life expectancy \> 8 weeks~* Karnofsky performance status ≥ 60~* WBC \>3,500/µL~* ALC \>350/mm3~* ANC \>1,500/mm3~* Platelet count \>100,000/mm3~* Hemoglobin \>10gm/dL~* AST, ALT and alkaline phosphatase \<2.5 times upper limit of normal (ULN)~* Bilirubin \<1.5 times ULN~* Creatinine \<1.5 mg/dL and/or creatinine clearance \>60cc/min~* Serum potassium, magnesium and calcium within normals levels (supplementation is allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Practice birth control during and for 2 months after treatment with IMA950 (both genders)~* Women of childbearing age must agree to use adequate contraceptive methods~* No significant active hepatic, renal, infectious or psychiatric disease~* No HIV, active hepatitis infection, or any other active severe infectious disease~* No history of autoimmune disease or immunosuppression~* No clinically significant cardiovascular event within 3 months before study entry or an increased risk for ventricular arrhythmia~* No malignancy other than glioblastoma that required treatment during the last 12 months~PRIOR and/or CONCURRENT THERAPY:~* See Disease Characteristics~* Completed radiotherapy and at least 4 cycles of adjuvant temozolomide~* Not be receiving steroids OR be on stable dose of steroids for ≥ 5 days prior to registration~* No other prior immunotherapy for glioblastoma~* No major surgery within 4 weeks prior to treatment start~* At least 4 weeks from cytotoxic therapies (incl. temozolomide)~* At least 2 weeks from non-cytotoxic therapies (e.g. interferon, tamoxifen)~* At least 3 weeks from bevacizumab~* No current treatment with imiquimod; prior use of imiquimod is allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).